Australia's most trusted
source of pharma news
Wednesday, 20 August 2025
Posted 19 August 2025 PM
Supply constraints of Viatris’ PBS listed pancreatic enzyme supplement Creon are expected to hit Australia this month and continue throughout year.
The US headquartered pharmaceutical company created from the merger of Mylan and Upjohn in 2020, has notified the TGA that it anticipates supply constraints related to Creon 25,000 unit and Creon 35,000 unit capsules between 21 August and 31 December 2025 due to an “unexpected global increase in demand”.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.